The efficacy of natiluzimab therapy was established in clinical trials.\u00a0 It soon, emerged, however that this “life changing” medication was potentially associated with a devastating<\/p>\n
infectious disorder of the brain, progressive multifocal leucoencephalopathy (PML).\u00a0 This side-effect resulted in withdrawal of the medication from clinical use for a period of time.\u00a0 Since re-introduction rigorous screening and monitoring techniques have been developed in order to prevent the development of PML.\u00a0 In an OnLine first publication Butzkueven and colleagues evaluated the long-term efficacy and safety of natiluzimab in patients with RRMS.\u00a0 Not surprisingly, the efficacy was very good, with marked reduction of relapse rates, being maintained for 5 years.\u00a0 Importantly, the risk of PML was low, with only 18 cases reported (total cohort 4821).<\/p>\n
<\/p>\n
Perhaps the screening strategies have indeed been effective.<\/p>\n
<\/p>\n
Read more at:\u00a0 http:\/\/jnnp.bmj.com\/content\/early\/2014\/02\/14\/jnnp-2013-306936.long<\/p>\n","protected":false},"excerpt":{"rendered":"
The efficacy of natiluzimab therapy was established in clinical trials.\u00a0 It soon, emerged, however that this “life changing” medication was potentially associated with a devastating infectious disorder of the brain, progressive multifocal leucoencephalopathy (PML).\u00a0 This side-effect resulted in withdrawal of the medication from clinical use for a period of time.\u00a0 Since re-introduction rigorous screening and […]<\/p>\n